Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

To be part of this study, you would need to have a diagnosis of haemophilia A and have received treatment for it before. You might be eligible if you haven't had issues with 'inhibitors' (where your body fights against the treatment) or if you've had them in the past but have been stable on preventive treatment for at least a year. Importantly, you shouldn't currently have any sign or suspicion of these inhibitors.

Another key requirement is that you are either about to start taking Jivi (damoctocog alfa pegol) or are already taking it, whether that's regularly to prevent bleeds, occasionally when a bleed happens, or on an intermittent basis. You would also need to agree to take part and provide your consent.

There are certain reasons why you might not be able to join. For example, if you're already in another study involving new treatments, or if you have other bleeding disorders apart from haemophilia A. Also, if there are specific medical reasons in the UK preventing you from taking Jivi, or if you're currently receiving treatment to get rid of inhibitors, you would not be able to participate.

This study is designed to observe how Jivi is used in real life, so it mainly involves collecting information about your existing treatment rather than prescribing new tests or specific visits. You would continue to take Jivi as prescribed by your doctor, whether that's regularly, when needed, or occasionally. The study team will gather details about your experience, including how well the medicine works for you and if you have any side effects. This information will likely come from your regular clinic visits and possibly questionnaires about your satisfaction. The total duration of your participation would depend on how long you remain on Jivi as part of your standard care.